IL164516A0 - 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors - Google Patents

2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors

Info

Publication number: IL164516A0
Authority: IL; Israel
Prior art keywords: quimolinyl; vla; inhibitors; processes; preparation
Prior art date: 2002-04-30

Application number

IL16451604A

Other languages

English (en)

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-30

Filing date

2004-10-12

Publication date

2005-12-18

2004-10-12 Application filed by Ucb Sa filed Critical Ucb Sa

2005-12-18 Publication of IL164516A0 publication Critical patent/IL164516A0/xx

Links

239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)

IL16451604A 2002-04-30 2004-10-12 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors IL164516A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02009746		2002-04-30
PCT/EP2003/003909 WO2003093237A1 (en)	2002-04-30	2003-04-15	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors

Publications (1)

Publication Number	Publication Date
IL164516A0 true IL164516A0 (en)	2005-12-18

Family

ID=29286106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16451604A IL164516A0 (en)	2002-04-30	2004-10-12	2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors

Country Status (24)

Country	Link
US (2)	US7638630B2 (de)
EP (2)	EP1870402A1 (de)
JP (1)	JP2005535583A (de)
KR (1)	KR100841165B1 (de)
CN (2)	CN101200450A (de)
AR (1)	AR039341A1 (de)
AT (1)	ATE384699T1 (de)
AU (1)	AU2003232472B2 (de)
BR (1)	BR0309719A (de)
CA (1)	CA2484954C (de)
CO (1)	CO5450243A1 (de)
CU (1)	CU23415B7 (de)
DE (1)	DE60318839T2 (de)
ES (1)	ES2298543T3 (de)
IL (1)	IL164516A0 (de)
MX (1)	MXPA04010673A (de)
MY (1)	MY135218A (de)
NO (1)	NO20045234L (de)
NZ (1)	NZ536180A (de)
PL (1)	PL373763A1 (de)
RU (1)	RU2315041C2 (de)
TW (2)	TWI267508B (de)
WO (1)	WO2003093237A1 (de)
ZA (1)	ZA200408447B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7638630B2 (en) *	2002-04-30	2009-12-29	Ucb Pharma S.A.	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
US7153889B2 (en)	2002-11-12	2006-12-26	Abbott Laboratories	Bicyclic-substituted amines as histamine-3 receptor ligands
EP1595870B1 (de)	2003-02-20	2015-09-23	Ajinomoto Co., Inc.	Verfahren zur herstellung eines phenylalaninderivats mit chinazolindionskelett und zwischenprodukt dafür
US7098222B2 (en)	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en)	2004-05-12	2007-04-17	Abbott Laboratories	Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7145005B2 (en)	2004-05-12	2006-12-05	Abbott Laboratories	2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
AU2006254772B2 (en)	2005-06-09	2011-06-02	Ucb Pharma S.A.	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
US8008496B2 (en)	2006-11-14	2011-08-30	Santen Pharmaceutical Co., Ltd.	1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents
WO2008125215A1 (en) *	2007-04-12	2008-10-23	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008125210A1 (en) *	2007-04-12	2008-10-23	Ucb Pharma, S.A.	Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008138592A1 (en) *	2007-05-14	2008-11-20	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) *	2007-05-16	2008-11-20	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2009074829A1 (en) *	2007-12-12	2009-06-18	Astrazeneca Ab	Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
EP2085407A1 (de)	2008-02-04	2009-08-05	Sahltech I Göteborg AB	Behandlung von idiopathischer thrombozytopenischer Purpura
KR20110010634A (ko) *	2008-05-12	2011-02-01	산텐 세이야꾸 가부시키가이샤	치환 옥시기를 가지는 2,2,4-트리메틸-6-페닐-1,2-디하이드로퀴놀린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
WO2011020874A1 (en)	2009-08-20	2011-02-24	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2015196086A1 (en) *	2014-06-20	2015-12-23	The University of Montana, Missoula, MT	NOVEL INHIBITORS OF SYSTEM Xc(-)
AU2015367977B9 (en)	2014-12-24	2020-02-06	Lg Chem, Ltd	Biaryl derivative as GPR120 agonist
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
EP4541422A3 (de)	2018-10-30	2025-06-25	Gilead Sciences, Inc.	Chinolinderivate als alpha4beta7-integrinhemmer
KR102659859B1 (ko)	2018-10-30	2024-04-25	길리애드 사이언시즈, 인코포레이티드	알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en)	2018-10-30	2023-07-13	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
CN112969700B (zh)	2018-10-30	2024-08-20	吉利德科学公司	作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102908219B1 (ko)	2019-08-14	2026-01-08	길리애드 사이언시즈, 인코포레이티드	알파 4 베타 7 인테그린의 저해용 화합물
JP7635962B2 (ja) *	2021-01-12	2025-02-26	国立大学法人山口大学	フルオロアルキル置換ビニルフルオロアルカンスルホニルアミドの製造方法
US20240301512A1 (en)	2021-01-29	2024-09-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
CN116410136B (zh) *	2023-03-03	2025-07-11	五邑大学	一种喹啉衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994004496A1 (en) *	1992-08-19	1994-03-03	Pfizer Inc.	Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5550139A (en) *	1994-01-03	1996-08-27	The Wichita State University	Serine protease inhibitors
WO1996018606A1 (en) *	1994-12-14	1996-06-20	Santen Pharmaceutical Co., Ltd.	Novel 1,3-dialkylurea derivatives
JP2920741B2 (ja) *	1994-12-14	1999-07-19	参天製薬株式会社	新規１，３−ジアルキルウレア誘導体
JPH0987291A (ja) *	1995-09-26	1997-03-31	Wakamoto Pharmaceut Co Ltd	新規なアラニン誘導体
EP0977989A1 (de)	1997-02-04	2000-02-09	Trega Biosciences, Inc.	4-substituierte chinolinderivate und kombinatorische 4-substituierte-chinolin-bibliotheken
AR016133A1 (es) *	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
BR9811730B1 (pt) *	1997-08-22	2014-04-08	Hoffmann La Roche	Derivados de n-aroilfenilalanina, uso dos mesmos, medicamentos contendo os mesmos.
WO2000015612A1 (en) *	1998-08-26	2000-03-23	Aventis Pharma Limited	Aza-bicycles which modulate the inhibition of cell adhesion
PL351987A1 (en)	1999-04-28	2003-07-14	Reddys Lab Ltd Dr	Substitution bicyclic-heterocyclic compounds, method of obtaining thereof, and use of such compounds to control adiposis and to reduce the level of cholesterol
US6280442B1 (en) *	1999-09-01	2001-08-28	Sdgi Holdings, Inc.	Multi-axial bone screw assembly
US6399599B1 (en) *	1999-10-13	2002-06-04	Novartis Ag	Substituted 2-oxo-1,4-diazacycloalkanes
US7638630B2 (en) *	2002-04-30	2009-12-29	Ucb Pharma S.A.	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
AU2006254772B2 (en)	2005-06-09	2011-06-02	Ucb Pharma S.A.	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

2003
- 2003-04-15 US US10/513,347 patent/US7638630B2/en not_active Expired - Fee Related
- 2003-04-15 ES ES03747411T patent/ES2298543T3/es not_active Expired - Lifetime
- 2003-04-15 EP EP07017712A patent/EP1870402A1/de not_active Withdrawn
- 2003-04-15 DE DE60318839T patent/DE60318839T2/de not_active Expired - Lifetime
- 2003-04-15 PL PL03373763A patent/PL373763A1/xx not_active Application Discontinuation
- 2003-04-15 CA CA2484954A patent/CA2484954C/en not_active Expired - Fee Related
- 2003-04-15 EP EP03747411A patent/EP1501801B1/de not_active Expired - Lifetime
- 2003-04-15 WO PCT/EP2003/003909 patent/WO2003093237A1/en not_active Ceased
- 2003-04-15 CN CNA2007101934884A patent/CN101200450A/zh active Pending
- 2003-04-15 CN CNA038097907A patent/CN1649842A/zh active Pending
- 2003-04-15 BR BR0309719-6A patent/BR0309719A/pt not_active IP Right Cessation
- 2003-04-15 RU RU2004135304/04A patent/RU2315041C2/ru not_active IP Right Cessation
- 2003-04-15 JP JP2004501376A patent/JP2005535583A/ja not_active Ceased
- 2003-04-15 NZ NZ536180A patent/NZ536180A/en not_active IP Right Cessation
- 2003-04-15 KR KR1020047017498A patent/KR100841165B1/ko not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010673A patent/MXPA04010673A/es active IP Right Grant
- 2003-04-15 AU AU2003232472A patent/AU2003232472B2/en not_active Ceased
- 2003-04-15 AT AT03747411T patent/ATE384699T1/de not_active IP Right Cessation
- 2003-04-23 AR ARP030101389A patent/AR039341A1/es unknown
- 2003-04-25 TW TW092109709A patent/TWI267508B/zh not_active IP Right Cessation
- 2003-04-25 TW TW094147669A patent/TWI268278B/zh active
- 2003-04-29 MY MYPI20031612A patent/MY135218A/en unknown
- 2003-04-29 CO CO03035403A patent/CO5450243A1/es not_active Application Discontinuation
2004
- 2004-10-12 IL IL16451604A patent/IL164516A0/xx unknown
- 2004-10-19 ZA ZA200408447A patent/ZA200408447B/en unknown
- 2004-11-01 CU CU20040252A patent/CU23415B7/es not_active IP Right Cessation
- 2004-11-29 NO NO20045234A patent/NO20045234L/no unknown
2009
- 2009-10-23 US US12/604,959 patent/US20100105681A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1501801B1 (de)	2008-01-23
TW200404061A (en)	2004-03-16
ZA200408447B (en)	2006-07-26
BR0309719A (pt)	2005-02-09
EP1870402A1 (de)	2007-12-26
US20100105681A1 (en)	2010-04-29
CN1649842A (zh)	2005-08-03
NZ536180A (en)	2005-04-29
MXPA04010673A (es)	2005-09-30
MY135218A (en)	2008-02-29
TWI267508B (en)	2006-12-01
AU2003232472B2 (en)	2008-09-18
CN101200450A (zh)	2008-06-18
CO5450243A1 (es)	2004-10-29
DE60318839T2 (de)	2009-01-22
WO2003093237A1 (en)	2003-11-13
PL373763A1 (en)	2005-09-19
TW200616960A (en)	2006-06-01
ATE384699T1 (de)	2008-02-15
DE60318839D1 (de)	2008-03-13
EP1501801A1 (de)	2005-02-02
RU2004135304A (ru)	2005-07-10
CA2484954A1 (en)	2003-11-13
RU2315041C2 (ru)	2008-01-20
ES2298543T3 (es)	2008-05-16
AU2003232472A1 (en)	2003-11-17
KR100841165B1 (ko)	2008-06-24
NO20045234L (no)	2005-01-18
US20080064720A1 (en)	2008-03-13
CA2484954C (en)	2010-02-09
KR20040106425A (ko)	2004-12-17
US7638630B2 (en)	2009-12-29
TWI268278B (en)	2006-12-11
CU23415B7 (es)	2009-09-08
JP2005535583A (ja)	2005-11-24
AR039341A1 (es)	2005-02-16

Publication	Publication Date	Title
IL164516A0 (en)	2005-12-18	2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors
IL164597A0 (en)	2005-12-18	Substituted 3-amino-thienoÄ2,3-bÜpyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
AU2003233010A8 (en)	2003-12-19	Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
IL165977A (en)	2010-12-30	Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL191926A0 (en)	2008-12-29	Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
IL191711A0 (en)	2008-12-29	1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
AU2003255845A8 (en)	2004-03-11	Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003243354A8 (en)	2003-12-19	Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
IL164798A0 (en)	2005-12-18	Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
AP2004003184A0 (en)	2004-12-31	Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same and methods for their use.
IL166710A0 (en)	2006-01-15	Process for the preparation of 4-ÄÄ4-ÄÄ-(2-cyanoethenyl)2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile
ZA200408423B (en)	2005-10-11	Novel tetrahydropyridine derivatives as renin inhibitors.
IL185035A0 (en)	2007-12-03	Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL166621A0 (en)	2006-01-15	Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
IL181766A0 (en)	2007-07-04	A process for the preparation of [1,4,5]-oxadiazepine derivatives
IL161428A0 (en)	2004-09-27	Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
AU2003212310A1 (en)	2003-10-13	(4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
IL176515A0 (en)	2006-10-05	1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
AU2003231920A8 (en)	2003-10-13	Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
PL374761A1 (en)	2005-10-31	N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
AU2003252467A1 (en)	2004-01-23	Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
AU2002953094A0 (en)	2002-12-19	Immunomodulating compositions, processes for their production and uses therefor
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
ZA200606542B (en)	2008-07-30	1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
IL182445A0 (en)	2007-07-24	Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide